ACADEMIC FRONTIERS
学术前沿
Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection
上一篇：Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus
下一篇：Association of HLA-DRB1 Single Nucleotide Polymorphisms with Left Ventricular Remodelling in Elderly Patients with Essential Hypertension
返回列表
